David M. Whitaker, MD
Associate Chief of Staff for Education
Physician
David.Whitaker@va.gov
Affiliation(s)
University of South Florida
Assistant Professor of Medicine, Department of Cardiology
Research
Research Area(s): Hyperlipidemia; Hypertrophic cardiomyopathy
Research Population: Veterans with atherosclerotic cardiovascular disease; Veterans with obstructive and non-obstructive hypertrophic cardiomyopathy
Research Methods: Multi-phase clinical trials
Recent Funding History
| Dates | Title | Funding Source and Type | Role |
|---|---|---|---|
| 2021 – 2029 | A randomized, double-blind, placebo- controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT) |
Novartis Industry Sponsored |
PI |
| 2023 – 2031 | A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VICTORION-1 PREVENT) |
Novartis Industry Sponsored |
PI |
| 2024 – 2027 | A randomized double-blind, placebocontrolled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease(LPA)(EXPANSION) |
Novartis Industry Sponsored |
PI |
| 2024 – 2029 | An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of EDG-7500 in Adults with Obstructive Hypertrophic Cardiomyopathy |
Novartis Industry Sponsored |
PI |
| 2022 – 2027 | (QI) VALOR Improve the cardiovascular (CV) health of Veterans by optimizing lipid management among those with ASCVD |
Novartis Industry Sponsored |
PI |
| 2021 – 2024 | Analysis of a care management model for psychopharmacological treatment in primary care | TVAREF Seed Grant | PI |